Citigroup reaffirmed a 'buy' rating on shares of Fortress Biotech.
2 reports, 1 independent
Updated Aug 15
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup reaffirmed a 'buy' rating on shares of Fortress Biotech.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
-
Fortress Biotech
company
Related events
- Citigroup restated a buy rating on the stock of Stora Enso.
- Citigroup raised shares to a buy rating for Fisher & Paykel Healthcare.
- Citigroup reissued a buy rating on ASML shares.
- Citigroup upgraded the stock rating for Truist Financial on June 26, 2025.
- Citigroup reiterated a market outperform rating for KB Home.